|
1. |
BibliographyCurrent World Literature |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 67-67
&NA;,
Preview
|
|
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
2. |
Transplantation |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 81-81
Richard Jones,
Preview
|
|
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
3. |
Bone marrow transplantation for autoimmune diseases |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 83-83
Robert Brodsky,
B. Smith,
Preview
|
|
摘要:
Autoimmune diseases afflict approximately 2% of the US population and span virtually every medical specialty. Most patients with autoimmune diseases have a normal life expectancy and are managed conservatively; however, a subset of patients have a progressive disease course associated with significant morbidity and mortality. High-dose cytotoxic therapy followed by autologous stem cell transplantation has been proposed as a novel treatment for severe autoimmune diseases. This review will focus on recent advances in the immunopathogenesis of autoimmunity and will review preliminary results of clinical trials employing hematopoietic stem cell transplantation for the treatment of autoimmunity.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
4. |
Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 87-87
Richard Champlin,
Issa Khouri,
Steven Kornblau,
Jeffrey Molldrem,
Sergio Giralt,
Preview
|
|
摘要:
Bone marrow transplantation was initially developed as a means to deliver supralethal doses of chemotherapy and radiation for treatment of malignancies. Myelosuppression is the dose-limiting toxicity for many chemotherapy drugs and whole-body radiation. Many malignancies exhibit a steep dose-response relationship to chemotherapy or radiotherapy. Bone marrow transplantation allows escalation of doses beyond those levels which produce severe bone marrow toxicity. Doses of many agents, particularly alkylating agents and whole body radiation, can be increased three-to fivefold above their conventional maximally tolerated dose. Marrow transplantation was considered a supportive care modality to restore hematopoiesis. It has become clear, however, that the high dose therapy does not eradicate the malignancy in many patients, and that the therapeutic benefit of allogeneic marrow transplantation is largely related to an associated immune-mediated graft-versus-malignancy effect.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
5. |
Lymphoproliferative disorders involving Epstein-Barr virus after hemopoietic stem cell transplantation |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 96-96
Laura Aguilar,
Cliona Rooney,
Helen Heslop,
Preview
|
|
摘要:
Lymphoproliferative disorders involving uncontrolled expansion of donor-derived B cells infected with Epstein-Barr virus (EBV) are a significant problem after hemopoietic stem cell transplantation. Risk factors, which include T cell depletion, major histocompatibility complex mismatch, and intensity of immunosuppression illustrate the importance of T cell immune surveillance. Recent studies have identified viral and host factors that affect the T-cell response to EBV. Monitoring EBV load in the blood by polymerase chain reaction allows early identification of high-risk patients and early institution of therapy. Adoptive immunotherapy approaches using donor T cells have proven effective and EBV-specific cytotoxic T lymphocytes have also been used successfully for prophylaxis. The simplest way of preventing EBV lymphoproliferation, however, may be to deplete B cells from the donor marrow prior to infusion to prevent the transmission of EBV-infected B cells.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
6. |
Bone marrow transplantation in multiple myeloma |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 102-102
Robert Schlossman,
Kenneth Anderson,
Preview
|
|
摘要:
Experience from around the world now suggests that high response rates can be achieved in patients with multiple myeloma treated with high-dose therapy followed by hematopoietic stem cell transplantation. However, patients are destined to relapse and few, if any, are cured. Major obstacles to cure are the excessive toxicity noted after allografting in multiple myeloma, contaminating tumor cells in multiple myeloma autografts, and most importantly, the persistence of minimal residual disease after high-dose therapy and either allogeneic or autologous stem cell transplantation. In this context, strategies are being developed to decrease the toxicity of allografting and to enhance allogeneic anti-multiple myeloma immunity after transplantation to improve outcome. To improve autografting, better ablative regimens, more efficacious purging of tumor cells from autografts, and enhancement of autologous anti-multiple myeloma immunity post-transplantation are modalities being tested to enhance overall and event-free survival.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
7. |
Drug resistance in lung cancer |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 109-109
Kazuto Nishio,
Takashi Nakamura,
Yasuhiro Koh,
Toshihiro Suzuki,
Hisao Fukumoto,
Nagahiro Saijo,
Preview
|
|
摘要:
The major problem in lung cancer chemotherapy is the emergence of inherent and acquired drug resistance of the cancer cells. Establishment of drug-resistant sublines and comparative investigations of such cell lines with their parental cells to determine their molecular, biologic, and biochemical properties are important research strategies. Genetic changes in tumor cells may induce changes in their biochemical properties and chemosensitivity. Many mechanisms that render tumor cells resistant have been identified, and they have provided new molecular targets for surrogate markers to predict chemosensitivity. The new categories of anticancer drugs, such as topoisomerase I inhibitors and taxanes, and non-cytotoxic new drugs, have been introduced clinically. It is important to define the molecular determinants of resistance to these drugs. The development of an appropriate model for overcoming drug resistance is one of the important issues that should be solved before carrying out further clinical trials.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
8. |
Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 116-116
Enrique Rozengurt,
Preview
|
|
摘要:
Lung cancers produce a variety of mitogenic neuropeptides and growth factors and express receptors for these signaling peptides leading to autocrine and paracrine loops that stimulate tumor cell proliferation and migration and promote neovascularization. The effects of these autocrine and paracrine factors are mediated by a variety of intracellular signal transduction pathways that ultimately converge on the regulation of cell cycle proteins whose expression and activity are abnormal in lung cancer cells. During the past year, further advances have been made in unraveling autocrine loops, signal transduction pathways, and cell cycle abnormalities in both small cell lung carcinoma (SCLC) and in non-SCLC. In addition, the hunt for novel tumor suppressor genes has continued. As our understanding of the fundamental cell and molecular biology of lung cancer increases, novel possibilities for translational research are emerging for improving the diagnosis, prognosis, and treatment of the disease.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
9. |
The role of screening in the management of skin cancer |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 123-123
Jonathan Wolfe,
Preview
|
|
摘要:
The incidence of skin cancer has been rising at an alarming rate for the past several years. This poses a significant public health problem in the United States. Detection and treatment of melanoma early in its course is critical for improved outcome. Of the approaches to cancer control that can reduce mortality from melanoma and nonmelanoma skin cancer, screening holds the greatest promise for a rapid and major impact. Prevention and early detection are crucial in reducing morbidity and mortality from skin cancer. For a number of reasons, however, the full effect of screening for both melanoma and nonmelanoma skin cancers has not been achieved. Controversy exists regarding who should perform screening, who should be screened, and whether screening should be performed at all. It is clear that melanoma and nonmelanoma skin cancer control programs combining primary prevention, education, and screening are in developmental stages. This review will discuss the advantages and disadvantages of screening for skin cancer.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
10. |
Pregnancy and exogenous hormones in patients with cutaneous malignant melanoma |
|
Current Opinion in Oncology,
Volume 11,
Issue 2,
1999,
Page 129-129
Rona MacKie,
Preview
|
|
摘要:
In this article, recent literature is reviewed with regard to possible hormonal influences on susceptibility to melanoma and prognosis once melanoma is developed. At the present time, there is little data to suggest that melanoma and pregnancy interact as far as prognosis is concerned for patients with stage 1 and stage 2 disease. Recent data have provided further reassurance that oral contraceptives are safe for patients who have had melanoma, and more data is required before a definitive statement can be made regarding hormone replacement therapy for women who have had stage 1 or 2 melanoma adequately treated.
ISSN:1040-8746
出版商:OVID
年代:1999
数据来源: OVID
|
|